FEDERAL RESERVE SYSTEM

Bank Holding Companies; Proposed De Novo Nonbank Activities; Louisiana Bancorp, Inc.

The organizations identified in this notice have applied, pursuant to section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.4(b)(1) of the Board's Regulation Y (12 CFR 225.4(b)(1)), for permission to engage *de novo* (or continue to engage in an activity earlier commenced *de novo*), directly or indirectly, solely in the activities indicated, which have been determined by the Board of Governors to be closely related to banking.

With respect to these applications, interested persons may express their views on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any comment that requests a hearing must include a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of that proposal.

The applications may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank indicated. Comments and requests for hearing should identify clearly the specific application to which they relate, and should be submitted in writing and received by the appropriate Federal Reserve Bank not later than the date indicated.

A. **Federal Reserve Bank of Atlanta** (Robert E. Heck, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. *Louisiana Bancorp, Inc.*, Crowley, Louisiana (leasing activities; Louisiana): To engage, through its subsidiary, Louisiana Bancorp Leasing Company, in the leasing of real property in accordance with the Board's Regulation Y. This activity would be conducted from an office located in Lafayette, Louisiana, serving the Lafayette, Louisiana greater metropolitan area. Comments on this application must be received not later than June 3, 1983.

2. *Louisiana Bancorp, Inc.*, Crowley, Louisiana (lending and financing activities; Louisiana): To engage, through its subsidiary, Louisiana Bancorp Lending Company, in making or acquiring loans and other extensions of credit such as would be made by a mortgage, finance, credit card or factoring company and in servicing loans and other extensions of credit for any person. These activities will be conducted from an office in Lafayette, Louisiana, serving southwest Louisiana. Comments on this application must be received not later than June 3, 1983.

B. **Federal Reserve Bank of Cleveland** (Lee S. Adams, Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. *PNC Financial Corp*, Pittsburgh, Pennsylvania (finance activities; Alaska): To engage, through its wholly-owned subsidiary, The Kissell Company, in making or acquiring and servicing for its own account and/or the account of others, loans and other extensions of credit. These activities will be conducted at an office located in the metropolitan area of Anchorage, Alaska and will serve the metropolitan area of Anchorage. Comments on this application must be received not later than June 10, 1983.

C. **Federal Reserve Bank of Kansas City** (Thomas M. Hoenig, Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Los Hacendados, Inc.*, Clayton, New Mexico (insurance activities; Union County, New Mexico): To engage through a proposed subsidiary, First Insurance Agency, Inc., in the sale of general insurance in a town with a population not exceeding 5,000. These activities would be performed in the Town of Clayton, serving all of Union County, New Mexico. Comments on this application must be received not later than June 10, 1983.

Board of Governors of the Federal Reserve System, May 11, 1983.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 83-13110 Filed 5-16-83; 8:45 am]

BILLING CODE 6210-01-M

GENERAL SERVICES ADMINISTRATION

[G-83-3]

Revocation of Delegation of Authority; Secretary of Defense

1. *Purpose.* This document revokes a 1975 delegation of authority to the Secretary of Defense.

2. *Effective date.* This document is effective June 16, 1983.

3. *Revocation.* The following 1975 delegation which authorized the Secretary of Defense to audit and retain all freight and passenger transportation documents paid by Department of Defense overseas offices is hereby revoked:

FPMR temporary regulation	Date	Subject
G-25	Dec. 30, 1975	Delegation of authority to the Secretary of Defense.

Dated: May 9, 1983.

Ray Kline,

Acting Administrator of General Services.

[FR Doc. 83-13160 Filed 5-16-83; 8:45 am]

BILLING CODE 6820-34-M

[G-83-34]

Delegation of Authority to the Secretary of Defense

1. *Purpose.* This delegation authorizes the Secretary of Defense to audit and retain other than international freight and passenger transportation documents paid by Department of Defense overseas offices.

2. *Effective date.* This document is effective June 16, 1983.

3. *Expiration date.* This document expires on January 1, 1988.

4. *Delegation.*

a. Pursuant to the authority vested in me by Section 322 of the Transportation Act of 1940, as amended (31 U.S.C. 3726), authority is delegated to the Secretary of Defense to:

(1) Continue the use of currently approved freight and passenger warrants, transportation orders, credit notes, and related transportation forms in overseas areas for the procurement of freight and passenger transportation and related services;

(2) Continue the use of currently approved Military Airlift Command (MAC) forms for the procurement of MAC contract airlift services;

(3) Audit and retain at Scott Air Force Base, Illinois, all payment vouchers and related transportation documents covering MAC contract airlift services, subject to test verification and reviews by GSA; and

(4) Audit and retain in overseas offices those transportation vouchers and related documents paid at such offices for other than international services, and non-English language documents for international services, subject to test verifications and reviews by GSA.

b. The Secretary of Defense may redelegate this authority to any officer, official, or employee of the Department of Defense.

c. This authority shall be exercised in accordance with the policies, procedures, and controls prescribed by the General Services Administration, and shall be exercised in cooperation with the responsible officers, officials, and employees thereof.

Dated: May 9, 1983.

Ray Kline,

Acting Administrator of General Services.

[FR Doc. 83-13161 Filed 5-16-83; 8:45 am]

BILLING CODE 6820-34-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 83C-0130]

Wilsa, Inc.; Filing of Color Additive Petition

AGENCY: Food and Drug Adminstration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Wilsa, Inc., has filed a petition proposing that the color additive regulations be amended to provide for the safe use of [phthalocyaninato(2-)] copper in coloring contact lenses.

FOR FURTHER INFORMATION CONTACT: Geraldine E. Harris, Bureau of Foods (HFF-334), Food and Drug Adminstration, 200 C St. SW., Washington, D.C. 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 706(b)(1), 74 Stat. 399-402 as amended (21 U.S.C. 376(b)(1))), notice is given that a petition (CP 3C0166) has been filed by Optacryl Division, Wilsa, Inc., P.O. Box 36142, Denver, CO 80236, proposing that the color additive regulations be amended to provide for the safe use of [phthalocyaninato(2-)] copper in coloring contact lenses.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: May 6, 1983.

Sanford A. Miller,

Director, Bureau of Foods.

[FR Doc. 83-12998 Filed 5-16-83; 8:45 am]

BILLING CODE 4160-01-M

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also sets forth a summary of the procedures governing committee meetings and methods by which interested persons may participate in open public hearings conducted by the committees and is issued under section 10(a) (1) and (2) of the Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat. 770-776 (5 U.S.C. App. I)), and FDA regulations (21 CFR Part 14) relating to advisory committees. The following advisory committee meetings are announced:

Vaccines and Related Biological Products Advisory Committee

Date, time, and place. June 7, 9 a.m., Rm. 121, Bldg. 29, 8800 Rockville Pike, Bethesda, MD.

Type of meeting and contact person. Open public hearing, 9 a.m. to 10 a.m., unless public participation does not last that long; closed committee deliberations, 10 a.m. to 4 p.m.; Jack Gertzog, National Center for Drugs and Biologics (HFN-6), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of vaccines and related biological products intended for use in the diagnosis, prevention, or treatment of human diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

Closed committee deliberations. The committee will review trade secret or confidential commercial information relevant to two pending investigational new drugs (IND's). This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Anesthesiology Device Section of the Respiratory and Nervous System Devices Panel

Date, time, and place. June 13 and 14, 9 a.m. Conference Rm. E., Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.

Type of meeting and contact person. Open public hearing, June 13, 9 a.m. to 10 a.m.; open committee discussion, 10 a.m. to 12 m.; closed committee deliberations, 1 p.m. to 2 p.m.; open committee discussion, 2 p.m. to 5 p.m.; open committee discussion, June 14, 9 a.m. to 5 p.m.; David S. Shindell, National Center for Devices and Radiological Health (HFK-430), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301-427-7226.

General function of the committee. The committee reviews and evaluates available data on the safety and effectiveness of devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the panel section leader before June 1, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of the proposed participants, and in indication of the approximate time required to make their comments. Presentations should be limited to 15 minutes. Persons or groups with similar views on the issues before the committee are requested, if possible, to consolidate their presentations and make a single presentation before the committee.

Open committee discussion. The committee will discuss premarket approval applications (PMA's) P830008 for a transcutaneous carbon dioxide monitor and P820043 for a high frequency jet ventilator.

Closed committee deliberations. The committee will review and discuss trade secret or confidential commercial information presented by the sponsor of PMA P820043 for a high frequency jet ventilator. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Circulatory System Devices Panel

Date, time, and place. June 24, 8:30 a.m., Rm. 703-727A, 200 Independence Ave. SW., Washington, D.C.

Type of meeting and contact person Open public hearing, 8:30 a.m. to 10:30 a.m.; closed presentation of data, 10:30 a.m. to 12:30 p.m.; open committee discussion, 1 p.m. to 4 p.m.; Glenn A. Rahmoeller, National Center for Devices and Radiological Health, Office of Medical Devices (HFK-450), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301-427-7559.

General function of the committee. The committee reviews and evaluates available data on the safety and effectiveness of devices currently in use

and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before June 10, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss recommendations from the North American Society of Pacing and Electrophysiology for the clinical evaluation of new pacemakers and will review a premarket approval application for the Cordis Gemini pacing system.

Closed presentation of data. Representatives from Kolff Medical will present trade secret or confidential commercial information regarding their clinical investigation of the artificial heart. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved for the separate portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairman determines will facilitate the committee's work.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairman's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

A list of committee members and summary minutes of meetings may be requested from the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday. The FDA regulations relating to public advisory committees may be found in 21 CFR Part 14.

The Commissioner, with the concurrence of the Chief Counsel, has determined for the reasons stated that those portions of the advisory committee meetings so designated in this notice shall be closed. The Federal Advisory Committee Act (FACA), as amended by the Government in the Sunshine Act (Pub. L. 94–409), permits such closed advisory committee meetings in certain circumstances. Those portions of a meeting designated as closed, however, shall be closed for the shortest possible time, consistent with the intent of the cited statutes.

The FACA, as amended, provides that a portion of a meeting may be closed where the matter for discussion involves a trade secret; commercial or financial information that is privileged or confidential; information of a personal nature, disclosure of which would be a clearly unwarranted invasion of personal privacy; investigatory files compiled for law enforcement purposes; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and information in certain other instances not generally relevant to FDA matters.

Examples of portions of FDA advisory committee meetings that ordinarily may be closed, where necessary and in accordance with FACA criteria, include the review, discussion, and evaluation of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, notably deliberative sessions to formulate advice and recommendations to the agency on matters that do not independently justify closing.

Dated: May 11, 1983.

Mark Novitch,

Acting Commissioner of Food and Drugs.

[FR Doc. 83-13112 Filed 5-16-83; 8:45 am]

BILLING CODE 4160-01-M

Pfizer Inc.; Tran-Q Plus Terramycin Premix; Withdrawal of Approval of NADA

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA) held by Pfizer, Inc., providing for use of Tran-Q plus terramycin Premix (oxytetracycline hydrochloride plus hydroxyzine hydrochloride) in cattle feed for increased feed efficiency and growth stimulation. The sponsor requested the withdrawal of approval.

EFFECTIVE DATE: May 27, 1983.

FOR FURTHER INFORMATION CONTACT: David N. Scarr, Bureau of Veterinary Medicine (HFV–214), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1846.

SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 E. 42d St., New York, NY 10017, is the holder of NADA 11–661, which provides for use of Tran-Q plus Terramycin Premix (oxytetracycline hydrochloride plus hydroxyzine hydrochloride) in making beef cattle feed for increased feed efficiency and growth stimulation.

The application was approved on April 15, 1959. Approval of this